Go Pro
→ Inside Nevada's 60 Million Ounce Gold Corridor (From Wall Street Logic) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$50.77
-5.8%		$55.57
$13.86
▼
$72.36
$1.60B0.71489,961 shs779,576 shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$76.08
-2.5%		$75.54
$35.20
▼
$82.94
$6.09B0.09516,558 shs408,240 shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$89.93
-4.9%		$96.79
$14.89
▼
$115.51
$6.26B-0.34793,730 shs1.99 million shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$49.85
-2.6%		$52.58
$27.07
▼
$61.76
$6.23B0.672.00 million shs2.49 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-5.84%-6.52%-13.12%-14.93%+142.34%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-2.46%-1.98%-4.16%+33.73%+109.41%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-4.89%-3.87%-12.19%+3.81%+477.96%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-2.62%+0.97%-14.35%-7.32%+47.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$50.77
-5.8%		$55.57
$13.86
▼
$72.36
$1.60B0.71489,961 shs779,576 shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$76.08
-2.5%		$75.54
$35.20
▼
$82.94
$6.09B0.09516,558 shs408,240 shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$89.93
-4.9%		$96.79
$14.89
▼
$115.51
$6.26B-0.34793,730 shs1.99 million shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$49.85
-2.6%		$52.58
$27.07
▼
$61.76
$6.23B0.672.00 million shs2.49 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-5.84%-6.52%-13.12%-14.93%+142.34%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-2.46%-1.98%-4.16%+33.73%+109.41%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-4.89%-3.87%-12.19%+3.81%+477.96%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-2.62%+0.97%-14.35%-7.32%+47.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.69
Moderate Buy$79.1555.91% Upside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
2.80
Moderate Buy$87.3814.85% Upside
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
2.82
Moderate Buy$133.0047.89% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
2.94
Moderate Buy$66.6933.78% Upside

Current Analyst Ratings Breakdown

Latest ANAB, ORKA, SRRK, and KNSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
9/23/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$90.00 ➝ $81.00
9/22/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$95.00
9/22/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/21/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$70.00
9/21/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$63.00 ➝ $70.00
9/15/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/15/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$72.00
9/15/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$64.00
9/15/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$60.00 ➝ $75.00
9/15/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$65.00 ➝ $70.00
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$234.60M6.41N/AN/A$1.34 per share37.89
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$840.85M7.06$0.77 per share98.27$7.44 per share10.23
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/A$9.69 per shareN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/A$2.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$13.23M$5.379.4520.81N/A82.37%112.00%2.20%11/3/2026 (Estimated)
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$59.01M$0.9778.4336.75N/A9.59%13.65%10.09%10/27/2026 (Estimated)
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$105.43M-$2.03N/AN/AN/AN/A-21.65%-20.88%11/11/2026 (Estimated)
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$377.94M-$3.45N/AN/AN/AN/A-160.19%-87.18%11/13/2026 (Estimated)

Latest ANAB, ORKA, SRRK, and KNSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/21/2026Q2 2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$0.4650$5.11+$5.5750$5.11$14.06 million$27.49 million
8/10/2026Q2 2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$0.5125-$0.55-$0.0375-$0.55N/AN/A
8/6/2026Q2 2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.8405-$0.84+$0.0005-$0.84$3.33 millionN/A
7/28/2026Q2 2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.2995$0.30+$0.0005$0.30$226.49 million$243.60 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
7.58
7.58
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.90
3.49
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A
38.51
38.51
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.77
7.02
7.02

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
53.95%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
56.44%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
31.50%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
51.98%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
23.49%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
10.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10429.61 million20.28 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
36678.02 million37.47 millionOptionable
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
6866.21 million50.66 millionN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
289121.79 million109.24 millionOptionable

Recent News About These Companies

Scholar Rock (NASDAQ:SRRK) Trading 6% Higher After Analyst Upgrade
September 24 at 1:20 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31042841
How Scholar Rock Holding Corporation (SRRK) Affects Rotational Strategy Timing
September 23 at 8:28 PM  |  news.stocktradersdaily.comN
Scholar Rock (NASDAQ:SRRK) Shares Up 6% Following Analyst Upgrade
September 22 at 10:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-scholar-rock-nasdaq-srrk-shares-up-6-following-analyst-upgrade-2026-09-22/
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 21, 2026
September 22 at 1:01 AM  |  biospace.comB
JPMorgan Chase & Co. Issues Positive Forecast for Scholar Rock (NASDAQ:SRRK) Stock Price
September 21 at 8:36 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31037331
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
September 21 at 8:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-scholar-rock-nasdaq-srrk-stock-price-expected-to-rise-jpmorgan-chase-co-analyst-says-2026-09-21/
Bank of America Corp DE Takes $53.47 Million Position in Scholar Rock Holding Corporation $SRRK
September 21 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-takes-5347-million-position-in-scholar-rock-holding-corporation-srrk-2026-09-21/
Analysts Offer Predictions for Scholar Rock FY2026 Earnings
September 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031625
Scholar Rock Holding (SRRK) Receives a Buy from Piper Sandler
September 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SRRK/pressreleases/4628246/scholar-rock-holding-srrk-receives-a-buy-from-piper-sandler/
Scholar Rock (NASDAQ:SRRK) Raised to Strong-Buy at Jefferies Financial Group
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-scholar-rock-nasdaq-srrk-raised-to-strong-buy-at-jefferies-financial-group-2026-09-17/
HC Wainwright Lowers Earnings Estimates for Scholar Rock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-lowers-earnings-estimates-for-scholar-rock-2026-09-17/
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?
September 16, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/scholar-rock-holding-srrk-wins-fda-approval-for-isembyld-can-add-on-use-scale-1837453/
Wedbush Reaffirms "Outperform" Rating for Scholar Rock (NASDAQ:SRRK)
September 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31025703
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions
September 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/scholar-rock-srrk-stock-fair-231604235.html
Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says
September 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scholar-rock-faces-early-isembyld-185203987.html
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946665-scholar-rock-strong-buy-on-fda-approval-sma-and-expansions-now-in-play
Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy
September 15, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/scholar-rock-downgraded-at-barclays-despite-fda-approval-of-sma-therapy/ar-AA2ch10y
Scholar Rock (NASDAQ:SRRK) Shares Down 7.1% - Here's What Happened
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-scholar-rock-nasdaq-srrk-shares-down-71-heres-what-happened-2026-09-15/
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
September 15, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/downgrades/26/09/61791446/this-cellectis-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-tuesday?utm_source=snapi
SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets
September 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/srrk-shares-pull-back-fda-203015507.html
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946041-scholar-rock-holding-corporation-srrk-discusses-fda-approval-and-clinical-impact-of-isembyld

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$50.77 -3.15 (-5.84%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$50.82 +0.04 (+0.09%)
As of 08:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$76.08 -1.92 (-2.46%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$75.75 -0.33 (-0.44%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Oruka Therapeutics stock logo

Oruka Therapeutics NASDAQ:ORKA

$89.93 -4.62 (-4.89%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$89.39 -0.54 (-0.60%)
As of 07:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$49.85 -1.34 (-2.62%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$49.78 -0.07 (-0.15%)
As of 08:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas